全球医用大妈行业市场前景及投资研究报告-培训课件外文版2024.5

INDUSTRIES

&

MARKETSMedical

Cannabis:

market

data&

analysisMarket

InsightsreportAugust

2023MARKET

INSIGHTSThis

report

is

part

ofour

Market

Insights

productGainabetterunderstandingofmarketsacross190+

geographicalentities

–

onaglobal,

regional,country,

and/orstatelevel.

Accessourdatavia

webinterface,download(XLS,

PDF,PPT),or

reports.Benefitfromour48-hourcustomerservice

guarantee.•

10

sectors:

advertising&media,consumers,countries,digital

sector,finance,health,

industrialsector,mobility,andtechnology•

1,000+

markets,

e.g.,

FinTech,Food,or

Robotics•

KPIs,

e.g.,

revenue,marketshares,prices,andvolume•

Features:Compare

countries®ions,

change

currencies,

selectvisualizations,

and/or

customize

downloads•

Usecases:

sales

planning,

investment

decision

support,resourceallocation,andportfolio

management10sectors190+geographicalentities1,000+markets400+reportsFind

out

more

on:https://www.Goto

Market

Insightscom/outlook/3CHAPTER

1OverviewThe

Medical

Cannabis

market

covers

allhigh-level

THC

and

CBD

medicineprescribed

by

a

doctorOverview:

Management

SummarySummaryCannabis-based

medical

products

are

already

used

when

encountering

avarietyof

symptoms

and

illnesses

suchaschronic

pain,

nausea

and

seizures,

to

nameafew.invest

inclinicaltrials

andapproved

medical

products

isJazz

PharmaceuticalsacquiringGWPharmaceuticals,

who

isthemanufacturerofEpidiolexandSativex.Forthefuture,we

expect

anincrease

inusageand

product

diversity

of

cannabis-based

medical

drugs,thus

providing

more

proof

oftheeffectiveness.

Thiswillallow

more

countries

tolegalize

medical

cannabisand

ease

theprocess

ofapproval

from

medical

authorities,

strengthening

thesupplyanddemand

ofcannabis-based

medical

products.TheUnitedStatesFood

andDrug

Administration(FDA)approved

Epidiolex

in2018

asthefirst

productwith

apurifiedformof

CBD.

A

drugapproval

byamedical

authorityensures

safetyandeffectiveness

forbothpatientand

doctor,increasing

theprobability

ofprescription

greatly.Depending

on

thecountry,different

medical

products

are

approved

though.Anexample

for

different

approval

status

between

countrysisSativex,which

isalready

approved

inseveral

countries

including

Germany,

UnitedKingdomandCanada,

but

itisnotyet

approved

intheUnitedStatesasof

2022.

Furthermore,there

arestill

countries,

where

theusageofmedical

cannabisisnotallowed.Withongoing

product

development,

investments,

and

Mergers

&Acquisitions,thefield

ofusecanstill

beexpanded.

Acurrent

example

(2021)

forthewillingness

to5Sources:Market

Insights

2023Medical

Cannabis

is

an

important

part

of

the

Cannabis

MarketOverview:

Market

DefinitionMarket

DefinitionTheMedical

Cannabis

market

includescannabinoid-based

medicine,

eitherlicensed

or

unlicensed

(notholding

marketing

authorization),which

is

suppliedthroughthehealthcare

system

and

prescribed

byadoctor

withtheprimary

focusof

mitigatingserious

disease

symptoms.

Itcanincludehighertetrahydrocannabinol(THC)levels

of

cannabidiol(CBD).6Sources:Market

Insights

2023Medical

Cannabis

accounted

for

26.26%

of

the

Cannabis

market

revenue

in2022Overview:

Market

DefinitionKeyTakeawaysInscopeOutof

scopeRevenue

intheMedical

Cannabis

market

isprojected

to

reach

US$12.92bn

in2023.Thismarket

includes:Thismarket

excludes:Revenue

is

expected

toshow

anannualgrowth

rate(CAGR(1)

2023-2028)

of13.16%,resulting

inamarket

volume

of

US$23.97bn

by2028.•Highertetrahydrocannabinol

(THC)levels

ofcannabidiol(CBD)•Lower

tetrahydrocannabinol

(THC)levels

cannabidiol(CBD)Inglobalcomparison,

most

revenue

will

begenerated

intheUnitedStates(US$11,320.00m

in2023).•Licensed

cannabinoid-basedmedicine

prescribed

bythedoctor,highertetrahydrocannabinol

(THC)levels

ofcannabidiol(CBD)•Recreational

cannabis•TherapeuticcannabisInrelation

to

totalpopulation

figures,per

person

revenues

of

US$0.36k

aregenerated

in2023.•Unlicensed

cannabinoid-basedmedicine

prescribed

byadoctor7Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:CHAPTER

2Market

NumbersMedical

Cannabis

revenue

is

estimated

to

increase

at

a

CAGR(1)

of

18.2%

from2016

to

2028Market

Size:

GlobalRevenue

forecast

inbillionUS$23.9721.7019.4417.15+18.2%(1)14.9812.9210.928.967.215.994.873.963.2120162017201820192020202120222023202420252026202720289Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:With

a

revenue

of

US$

10.2

billion,

Americas

is

the

biggest

market

amongselected

regions

in

2022Market

Size:

Regional

Comparison

(1/2)Revenue

forecast

inbillionUS$+13.9%(1)22.2+15.5%(1)10.21.1+16.5%(1)0.50.0%(1)+20.1%(1)0.20.10.10.10.120280.0202220282022202220282022202820222027EuropeAfricaAmericasAsiaAustralia10

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023With

a

revenue

of

9.6

billion

US$,

the

United

States

are

the

biggest

marketamong

selected

countries,

in

2022Market

Size:

Regional

Comparison

(2/2)Revenue

forecast

inbillionUS$+13.9%(1)21.0+13.9%(1)9.61.2+15.6%(1)+16.3%(1)0.60.5+14.8%(1)0.40.30.20.10.12022202820222028202220282022202820222028United

StatesCanadaGermanyAustraliaSouthKorea11

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023The

average

revenue

per

user

in

the

Medical

Cannabis

market

is

estimated

todecrease

from

2016

to

2028Market

Size:

GlobalAveragerevenue

peruserforecast

inUS$1,4001,219.01,155.01,2001,0008006004002000883.6648.2509.42020402.12028390.62021393.12022391.82027379.82026361.52023361.72024368.52025201620172018201912Sources:Market

Insights

2023The

United

States

have

the

biggest

average

revenue

per

user

in

2022Market

Size:

Regional

Comparison

(1/2)Averagerevenue

peruserforecast

inUS$1,8001,604.61,575.91,541.91,6001,4001,2001,0008001,480.41,500.31,460.31,463.61,442.51,432.41,427.41,405.51,382.61,378.1600340.82027352.02028327.92026308.52017300.32024314.12025400285.72023274.62018270.72019270.82022258.92020250.52021147.320162000United

StatesEurope13Sources:Market

Insights

2023With

an

average

revenue

per

user

of

2227.0

US$,

Germany

is

the

biggest

marketamong

selected

countries,

in

2022Market

Size:

Regional

Comparison

(2/2)Averagerevenue

peruserforecast

inUS$3,5003,046.72,835.03,0002,5002,0001,5001,0005002,586.62,514.91,871.72,458.81,832.72,393.01,786.62,368.72,335.01,742.92,288.11,705.12,251.41,670.42,212.81,584.12,227.01,637.81,691.81,213.61,679.61,161.51,653.91,087.41,618.21,010.51,539.8930.81,017.91,038.6993.1951.8970.2907.1922.8936.102016201720182019202020212022202320242025202620272028GermanyCanadaAustralia14Sources:Market

Insights

2023The

number

of

Medical

Cannabis

users

is

estimated

to

increase

from2016

to2028Market

Size:

GlobalUsersforecast

inmillions59.6605040302010055.451.246.541.435.727.822.914.29.25.53.42.6201620172018201920202021202220232024202520262027202815Sources:Market

Insights

2023In2022,

the

United

States

have

more

users

of

Medical

Cannabis

than

EuropeMarket

Size:

Regional

Comparison

(1/2)Usersforecast

inmillions1413.112.01210811.010.09.07.92.06.85.864.73.843.13.12.92.72.52.52.32.00.11.71.420.90.60.40.202016201720182019202020212022202320242025202620272028United

StatesEurope16Sources:Market

Insights

2023With

6.8

million

users,

the

United

States

are

the

biggest

market

among

selectedcountries,

in

2022Market

Size:

Regional

Comparison

(2/2)Usersforecast

inmillions141210813.0512.0411.0210.008.960.437.910.386.840.335.770.2864.683.790.1843.080.152.500.120.480.580.22

0.240.532.020.100.000.230.060.630.2020.170.010.120.150.020.040.090.250201620172018201920202021202220232024Germany2025202620272028United

StatesCanada17Sources:Market

Insights

2023Comparatively,

the

United

States

have

the

greatest

number

of

medicalcannabis/

CBD

users,

whilst

Germany

has

the

leastConsumer

Insights(1/4)Medical

cannabis/CBD

user(1)85%75%57%43%25%15%Cannabis/CBDuserNon-userUnited

StatesUnited

KingdomGermany18

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

U.S.:

n=2,049,

UK:n=

2,087;

Germany:n=2,071Consumer

Insights

202312%

of

consumers

in

the

United

Kingdom

and

6%

in

Germany

used

medicalcannabis/CBD

in

the

last

12

monthsConsumer

Insights(2/4)Medical

cannabis/CBD

usage(1)85%75%57%20%15%12%8%8%6%6%5%4%Inever

took

medical

cannabisprescribed

byadoctorIcurrently

takeitInthe

last12

monthsbutnot

currentlyLonger

than12

monthsagoUnited

StatesUnited

KingdomGermany19

Notes:Sources:(1):

“When

was

the

last

time

youused

medical

cannabis

/CBD?”;(single-pick);

U.S.:

n=2,049,

UK:n=

2,087;

Germany:n=2,071Consumer

Insights

2023Most

consumers

in

the

United

states

prefer

taking

medical

cannabis/CBD

in

theform

of

edibles,

whilst

dropsfor

oral

intake

with

water

is

popular

with

GermansConsumer

Insights(3/4)Method

oftakingcannabis(1)23%21%17%17%16%16%16%15%13%11%10%11%10%7%9%9%

9%Tea8%7%7%7%6%6%5%4%4%2%2%

2%

2%1%

1%

1%1%

1%

1%EdiblesSmoke

itDon’t

know

CapsuleforDrops

fororal

intakewith

waterCream/lotion

Drops

fororal

intakeSolution

for

Oily

solution

Oily

solution

Iwouldn’tinhalation

forintake

forintake

takecannabiswithout

water

with

wateroral

intakewithout

watereven

ifthedoctorprescribes

itUnited

StatesUnited

KingdomGermany20

Notes:Sources:(1):

“Medical

cannabis

is

offeredin

different

forms.Which

formwould

youpreferforintake,

no

matterif

youhave

everused

it

ornot?”;(single-pick);

U.S.:

n=2,049,

UK:

n=

2,087;

Germany:n=2,071Consumer

Insights

202333%

of

consumers

in

the

United

States

and

28%

in

Germany

feel

that

cannabisshould

be

legalized

for

everyoneConsumer

Insights(4/4)Attitudestowards

medical

cannabis/CBD(1)43%38%38%33%32%28%26%26%26%25%24%23%21%20%

20%19%18%18%16%15%13%Ihavealready

usedmedical

cannabis/CBD

cannabisshouldbelegal

foreveryoneTheuseofMedical

cannabis/CBDis

agoodalternative

totraditionalmedical

productsIwould

prefer

medicalcannabis/CBDover

medical

cannabis/CBD

risksof

usingmedicalchemical

medicationUnited

KingdomIcanimagine

using

Iamworried

abouttheIdon’twantcannabisto

belegalcannabis/CBDUnited

StatesGermany21

Notes:Sources:(1):

“Which

ofthese

statements

regardingmedical

cannabis

/CBDapply

to

you?”;(multi-pick);

U.S.:

n=2,049,

UK:n=

2,087;

Germany:n=2,071Consumer

Insights

202348%

of

males

and

38%

of

females

in

the

United

States

are

medicalcannabis/CBD

usersConsumer

Insights:United

States(1/4)Medical

cannabis/CBD

user(1)62%52%48%38%Cannabis/CBDuserNon-userMalesFemales22

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

U.S.:

n=2,049,

males;n=999,

females;n=1,050Consumer

Insights

202345.4%

of

the

medical

cannabis/CBD

users

in

the

United

States

are

femaleConsumer

Insights:United

States(2/4)Medical

cannabis/CBD

usersbygender202145.4%54.6%FemaleMale23

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

U.S.:

n=2,049,

males;n=999,

females;n=1,050Consumer

Insights

202354.3%

of

the

medical

cannabis/CBD

users

in

the

United

States

are

between

18and

39

years

oldConsumer

Insights:United

States(3/4)Medical

cannabis/CBD

usersbyage1.6%202128.7%25.6%21.0%13.7%5.2%4.3%30-39

years20-29

years40-49

years50-59

years60-69

years18-19

years70

years

and

older24

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

U.S.:

n=2,049,

males;n=999,

females;n=1,050Consumer

Insights

2023Most

male

consumers

in

the

United

States

take

medical

cannabis/CBD

toreduce

pain,

whilst

most

females

use

it

to

reduce

anxietyConsumer

Insights:United

States(4/4)Reasons

oftakingcannabis(1)20%20%19%18%18%17%17%16%15%

15%9%7%7%6%5%5%4%3%2%2%2%

2%OtherReduce

painReduceanxietyRelaxationandstressreliefSleep

aidReducedepressionImproveheart

health

cancer-relatedsymptomsAlleviateSubstanceabusetreatmentReduce

skinproblemsTreatmentof

epilepsyMalesFemales25

Notes:Sources:(1):

“Forwhich

ofthese

benefits

do

ordid

youuse

medical

cannabis

/CBD?”;(multi-pick);

U.S.:

n=2,049,

males;n=999,

females;n=1,050Consumer

Insights

202329%

of

males

and

22%

of

females

in

the

United

Kingdom

are

medicalcannabis/CBD

usersConsumer

Insights:United

Kingdom

(1/4)Medical

cannabis/CBD

user(1)78%71%29%22%Cannabis/CBDuserNon-userMalesFemales26

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

UK:n=2,087,

males;n=1,023,

females;

n=1,064Consumer

Insights

202343.4%

of

the

medical

cannabis/CBD

users

in

the

United

Kingdom

are

femaleConsumer

Insights:United

Kingdom

(2/4)Medical

cannabis/CBD

usersbygender202143.4%56.6%FemaleMale27

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

UK:n=2,087,

males;n=1,023,

females;

n=1,064Consumer

Insights

202361%

of

the

medical

cannabis/CBD

users

in

the

United

Kingdom

are

between18and

39

years

oldConsumer

Insights:United

Kingdom

(3/4)Medical

cannabis/CBD

usersbyage202130.7%30.3%17.6%10.0%4.7%

4.6%2.1%20-29

years30-39

years40-49

years50-59

years60-69

years18-19

years70

years

and

older28

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

UK:n=2,087,

males;n=1,023,

females;

n=1,064Consumer

Insights

2023Most

male

consumers

in

the

United

Kingdom

take

medical

cannabis/CBD

toreduce

pain,

whilst

most

females

use

it

to

reduce

anxietyConsumer

Insights:United

Kingdom

(4/4)Reasons

oftakingcannabis(1)10%10%9%9%8%8%8%

8%7%5%5%4%4%3%3%3%2%2%2%2%1%1%Reduce

painSleep

aidReduceanxietyReducedepressionRelaxationandstressreliefReduce

skinproblemsImproveheart

healthTreatmentof

epilepsy

cancer-relatedsymptomsAlleviateSubstanceabusetreatmentOtherMalesFemales29

Notes:Sources:(1):

“Forwhich

ofthese

benefits

do

ordid

youuse

medical

cannabis

/CBD?”;(multi-pick);

UK:n=2,087,

males;n=1,023,

females;

n=1,064Consumer

Insights

202318%

of

males

and

12%

of

females

in

Germany

are

medical

cannabis/CBD

usersConsumer

Insights:Germany

(1/4)Medical

cannabis/CBD

user(1)88%82%18%12%Cannabis/CBDuserNon-userMalesFemales30

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

Germany:n=2,071,

males;n=1,093,

females;

n=978Consumer

Insights

2023Only

38.1%

of

the

medical

cannabis/CBD

users

in

Germany

are

femaleConsumer

Insights:Germany

(2/4)Medical

cannabis/CBD

usersbygender202138.161.9FemaleMale31

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

Germany:n=2,071,

males;n=1,093,

females;

n=978Consumer

Insights

202358.8%

of

the

medical

cannabis/CBD

users

in

Germany

are

between

18

and

39years

oldConsumer

Insights:Germany

(3/4)Medical

cannabis/CBD

usersbyage202130.2%28.6%17.3%12.6%4.4%

3.8%

3.1%20-29

years30-39

years40-49

years50-59

years18-19

years60-69

years70

years

and

older32

Notes:Sources:(1):

“Recode

basedon

Medical

cannabis

/CBDusage”;

(single-pick);

Germany:n=2,071,

males;n=1,093,

females;

n=978Consumer

Insights

2023InGermany,

most

male

consumers

take

medical

cannabis/CBD

to

reducedepression,

whilst

most

females

use

it

to

reducepainConsumer

Insights:Germany

(4/4)Reasons

oftakingcannabis(1)6%6%5%5%

5%5%4%4%3%3%3%2%2%2%

2%2%2%1%1%1%1%

1%OtherReducedepressionReduce

painSleep

aidRelaxationandstressreliefReduceanxietyImproveheart

healthTreatmentof

epilepsyReduce

skinproblemsSubstance